Shaily Engineering Plastics 2026: ₹3,404 TP on GLP-1

Coverage initiation and the core thesis

Shaily Engineering Plastics (referred to as SHEP/SHAILY in market commentary) has seen fresh coverage initiation with a BUY rating and a target price (TP) of ₹3,404, implying 26% upside potential. The valuation basis cited is 45x FY28E P/E, described as roughly +1 standard deviation of its 10-year mean. The stated investment view hinges on a mix of strong earnings growth, cash generation, and an expansion in return ratios. The same note flags that the company’s healthcare segment has made “significant strides” over the past year. The near-term debate, however, is not only about growth but also whether the current price already discounts a meaningful part of that trajectory.

Why GLP-1 devices are driving attention

The healthcare momentum is linked to rising demand for GLP-1 and insulin delivery devices. A key trigger highlighted is the semaglutide patent expiry in March 2026 in some major emerging markets, including India, Canada, and Brazil, which can open the door to generic drug launches and the associated device ecosystem. In multiple GLP-1 engagements, SHEP is described as being selected as the sole device supplier, indicating strong customer confidence in its manufacturing and execution capability. Market commentary also ties the opportunity to the broader global adoption of GLP-1 therapies for diabetes and obesity. One note referenced the GLP-1 market as expected to surpass $100 billion by 2030.

Capacity expansion plan: fivefold increase by FY28

A major operational datapoint is the plan to augment GLP-1 pen capacity by about 5x to over 150 million units by FY28. The investment case links this to volume commitments from key healthcare customers and the company’s ability to scale production while expanding margins. Separately, another piece of commentary mentions an Abu Dhabi expansion plan: a ₹300-₹350 crore investment for a scalable facility manufacturing pen and auto-injectors, targeting 75 million units per year of capacity. These datapoints position capacity build-out as central to the healthcare-led growth narrative.

FY26 performance and margin improvement

The coverage note reports that in FY26, SHEP clocked 26%/59%/82% year-on-year growth in revenue/EBITDA/PAT. It also states that EBITDA margin expanded to 28.2% in FY26 from 22.4% in FY25, aided by the healthcare segment. Another data point cited is Q3 FY26 performance, with revenue at ₹251 crore (up 27% YoY) and EBITDA at ₹66 crore (up 43% YoY). In narrative terms, these figures are being used to support the claim that the business mix is shifting toward higher-margin, precision healthcare manufacturing.

FY26 to FY28 outlook: growth, margins, and return ratios

The forward estimates highlighted are 29%/38%/43% CAGR in revenue/EBITDA/PAT over FY26-28. The same view expects 32%+ EBITDA margin in FY28, again linked to volume commitments from key healthcare customers. Return metrics are projected to expand to RoE of ~28% and RoCE of ~36% in FY28E. Operating cash flow is cited at around ₹800 crore (from ₹8 billion) over FY26-28, positioned as a key funding support for capacity expansion and execution.

Stock moves, institutional interest, and what the market is pricing in

The stock’s sharp rerating is central to the risk discussion. The coverage note states the stock price has risen over 50% in a year and around 5x/10x in the last 2/3 years, respectively, on the back of strong earnings growth. Separately, market reporting notes SHAILY gained over 30% between April 22 and April 28, 2026, reaching a three-month high near ₹2,500. The move is attributed to its strategic shift toward healthcare and rising interest in GLP-1 delivery devices. The same commentary references institutional interest, including a stake increase by Smallcap World Fund.

Alternative target frameworks also circulating

Alongside the ₹3,404 TP, another independent BUY framework mentioned a closing price of ₹2,157 on 27 March 2026 and outlined a 3-year target price of ₹3,477 (March 2029) and a 5-year target price of ₹5,220 (March 2031). While the time horizons and assumptions differ across notes, the common anchor remains the healthcare-device scale-up and the potential to serve global pharma customers in pen injectors and auto-injectors.

Key risks highlighted by analysts

The coverage note flags a clear risk: after a steep rally, any large earnings miss could lead to a de-rating. With valuation anchored to a high multiple (45x FY28E P/E), execution consistency and customer ramp-up matter. The same set of commentary also includes a valuation caution that the opportunity may be real, but the valuation is already demanding, especially after recent price momentum.

Snapshot table: key facts and figures cited

Conclusion

The current set of notes on Shaily Engineering Plastics converges on one point: the healthcare segment, particularly GLP-1 and insulin delivery devices, is now central to the growth and margin story. The cited numbers show sharp FY26 improvement, ambitious FY28 capacity and margin targets, and a valuation that assumes sustained execution. The next markers for investors, based on what is already outlined, are progress on capacity additions, volume commitments translating into revenue, and whether margins and returns track toward the FY28 expectations.